281 related articles for article (PubMed ID: 27695618)
1. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Einsele H; Schreder M
Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
3. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.
Weisel K
Onco Targets Ther; 2016; 9():6037-6048. PubMed ID: 27785050
[TBL] [Abstract][Full Text] [Related]
5. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
Trudel S; Moreau P; Touzeau C
Onco Targets Ther; 2019; 12():5813-5822. PubMed ID: 31410026
[TBL] [Abstract][Full Text] [Related]
6. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
7. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
8. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
Chen WC; Kanate AS; Craig M; Petros WP; Hazlehurst LA
Cancer Manag Res; 2017; 9():307-314. PubMed ID: 28744161
[TBL] [Abstract][Full Text] [Related]
9. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
Taniwaki M; Yoshida M; Matsumoto Y; Shimura K; Kuroda J; Kaneko H
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018014. PubMed ID: 29531651
[TBL] [Abstract][Full Text] [Related]
10. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Pazina T; James AM; MacFarlane AW; Bezman NA; Henning KA; Bee C; Graziano RF; Robbins MD; Cohen AD; Campbell KS
Oncoimmunology; 2017; 6(9):e1339853. PubMed ID: 28932638
[TBL] [Abstract][Full Text] [Related]
11. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM; Kelly K; Jean GW
Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
13. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic antibodies for multiple myeloma.
Ishida T
Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
Magen H; Muchtar E
Ther Adv Hematol; 2016 Aug; 7(4):187-95. PubMed ID: 27493709
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Pharmacology of Elotuzumab.
Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
[TBL] [Abstract][Full Text] [Related]
20. Elotuzumab: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
